Directorate General Of Health Services

Public Health

INSTITUTE OF SEROLOGY KOLKATA

1. Introduction: Institute of Serology Kolkata was established on 17th September, 1912 and is now a subordinate office of Directorate General of Health Services, under the Ministry of Health & F.W. of India. Current activities of the Institute are as under;

i. Production of various quality diagnostic reagents like Antigen, species specific Antisera, Anti H Lectin etc. and supply to the Government and Non-Government Institutions like Forensic Science Laboratories and Hospitals all over the country.

ii. Forensic Serology for determination of origin of species of different biological exhibits and undertake blood group serology in case the species origin is human.

iii. Institute also serve as National Referral Laboratory for identification of Measles and Rubella

iv. Training of Laboratory Technicians in various fields of Serology and Sexually Transmitted Diseases and imparting training in Forensic Serology to post graduate students of Forensic Medicine.

v. Referral laboratory/Centre for A, B, O Blood grouping & Rh typing, V. D. Serology, Isolation of Polio Virus.

2. Administrative Activities

2.1. Staff Strength:

• Total Sanctioned Strength of staff -93

• Staff in position at IOSK -60

• Vacant positions at IOSK -36

• % vacant position at IOSK -35.48% Consolidated status of the staff is given in the table No.1.

Table No. 1

Group-wise staff position of CRI Kasauli

S. No.	Staff	sanctioned strength	Staff in-position	Vacant positions	% Vacancies
1	Group-A	9	6	3	33.33
2	Group-B (Gaz)	2	0	2	100.00
3	Group-B(NG)	5	1	4	80.00
4	Group-C (Technical)	53	32	21	39.62
	Group C (Ministerial)	24	21	3	12.50
	Total	93	60	33	35.48

Detailed staff position is given in Annexure 1

2.2Budget Performance:

BE 2015-16 is Rs. 630.00 lakh (Plan Rev Rs. 55.00 lakh and Non-plan Rs. 575.00 lakh)
RE 2015-16 Rs. xx lakh (Plan Rev Rs. 7.04 lakh and Non-plan Rs. 284.49 lakh)
FE 2015-16 Rs. xx lakh (Plan Rev Rs. 45.50 lakh and Non-plan Rs. 594.39 lakh).
Expenditure 2015-16 xx
% Utilization against FE is xx (Plan Rev 7.82% and Non-plan 50.45%).
BE 2015-16 is Rs. 634.00 lakh (Plan Rs. 34.00 lakh and non-plan Rs. 600.00 lakh)

Consolidated allocation & utilization of budget 2013-14 is given in table No. 2.

Table No. 2

Budget Provisions

(Rs. in Lakh)

S. No	Year	Plan	Non-Plan	Total
1	BE 2015-16	55.00	575.00	630.00
2	RE 2015-16	55.00	575.00	630.00
3	FE 2015-16			0
4	Expenditure 2015-16			0
5	% Expenditure against FE			0
6	BE 2016-17	34.00	600.00	634.00

3. Technical support Services:

3.1. Medico-legal Section:

S. No	Samples	No. of fresh samples received
I	Forensic Cases)	1036
ii	Forensic Exhibits	4511
iii	Items for Species determination	4984
iv	Items for Blood Grouping	1111
	Total

3.2. VD Serology

S. No	Samples	No. samples Received	No. Of samples found Positive	No. of samples for which Report Given
i	Antenatal cases	-	-	-
ii	STD clinic samples	2537	90	2537
iii	Ref. Lab. Pool	-	-	-
	Total	2537	90	2537

3.3. STD/Bacteriology Section

S. No	Samples	No. samples Received	No. Samples Positive test 1	No. Of samples positive test 2
i	Syphilis	2637	90 VDRL	137 TPHA
ii	Candida	1992	206 Gram stain	252 Culture
iii	Gonorrhea	1839	06 Direct Smear	00 Culture
iv	B. Veginosis	1992	238 KOH
v	Hepatitis B	2329	20 Elisa	29 Immu Rech
vi	Hepatitis C	92	0	2 imm rech
vii	PAP Smear	1755	0	0
viii	HSV – 2	366	48 (ELISA
ix	Trichomonas Vaginalis	1992	415 Wet Mount	496 Culture
x	C. Trachomatis	184	59 ELISA
xi	Non Herpetic Syndrome	124	3 GiMSA
xii	Herpetic Syndrome	68	13 GIMSA
xiii	CMV	00	00 ELISA
	Total

Production Division

3.4. Antigen and Antibody Production Division (Production, Demand and supplies)

Quantity in Number of Ampoules/vials

S. No	Vaccine / Anti-sera	Quantity manufactured	Demand received	Quantity supplied
i	VDRL Antigen	3640 amp	3340 amp	3340 amp
ii	Antisera against animal species	4890 ml	2279 ml	4270 ml
	Total

3.5. BGRC Section

Quantity in numbers of Ampoules/Vials

S. No	Vaccine / Anti-sera	Quantity manufactured	Demand received	Quantity supplied
i	Anti-H Lectin	2600 ml
ii	A-1 Lectin	-	-	-
iii	Blood Grouping antigen	537
iv	Anti D (Rh factor)	19
	Total

4. Quality Control Division

S. No	Lots	No. of Lots Received No. of Lots Tested	No. of Lots Cleared	No. of Lots Rejected
i	Anti-H Lectin	72	72	72
ii	Species Anti-serum	18	18	18
iii	VDRL Antigen	05	05	05
	Total	95	95	95

5. Surveillance section

5.1. National Polio Laboratory

S. No	Samples	Numbers
i	Total cases/samples received	13024
ii	NPEV positive	1076
iii	L20 B Positive	127
iv	Environment Sample received	208
v	L20 B Positive	226

5.2. Measles Laboratory

5.2.1. Measles samples

S. No	Samples	Numbers
i	Total cases/samples received	972
ii	No. of samples tested	972
iii	No. of samples found Positive	481
iv	No. of samples found Negative	485
v	No. of samples found equivocal	00

5.2.2. Rubella samples

S. No	Samples	Numbers
i	Total cases/samples received	432
ii	No. of samples tested	432
iii	No. of samples found Positive	155
iv	No. of samples found Negative	277
v	No. of samples found equivocal	00

BCG VL GUINDY – BRIEF ON ACTIVITIES

1.Introduction:

1.1. Organization

BCGVL Guindy was established in 1948 and currently is a sub-ordinate office of the Directorate General of Health Services (DGHS) under the Ministry of Health and Family Welfare of the Government of India, situated at Guindy, Chennai (Tamilnadu) near King Institute of Preventive Medicine. The institute has a huge complex, which is divided in five major sub-sections i.e. Establishment, Production Division, Quality Control Division, Animal House and Warehousing & Marketing. The other major facilities are Containerization, sterilization, Physical inspection.

1.2. Functions:

The major functions of the institute are production of BCG Vaccine (10 doses) for control of childhood Tuberculosis and supply to Expanded Programme of Immunization (EPI). Institute also manufactures therapeutic BCG Vaccine for management of bladder cancer.

2. Staff Strength

sanctioned strength -113
Staff in-position -95
Requirement as cGMP -151
Existing staff suitable -94
New psts to be created -57

3. Budget Provisions:

Budget Estimates 2015-16 -Rs. 2315.00 lakh
RE (2015-16) proposed -Rs. 1684.00 lakh
FE 2015-16 -Rs. 1465.00 lakh • Actual expenditure 2015-16 -Rs. 1384.85 lakh
BE (2016-17) proposed - Rs. 2255.00lakh

4. Physical Performance of BCG

Installed capacity for production of BCG vaccine of 800 lakh doses per annum.
The Institute was meeting 100% of demand of BCG vaccines in the country, since 2002-03.
However, after the suspension of the manufacturing license in Jan., 2008, the production and supply of the BCG Vaccine from the institute was stopped.

5. Up-gradation of BCG vaccine manufacturing facility:

MOH&FW has taken a decision in a meeting under the Chairmanship of Secretary (H) on 1.3.2011, wherein it was decided that the BCGVL will be revived and a new cGMP compliant BCG vaccine manufacturing facility will be created at the exiting site.
SFC was approved for creation of new facility for manufacturing of BCG vaccine and for renovation of Allied facilities at BCGVL.
Ms. HLL was engaged for up-gradation of BCG vaccine manufacturing facility at BCGVL Chennai and to make it cGMP compliant with a cost of Rs. 64.72 Crores.

Status of completion of new facility as on date;

• Construction & Civil Works -Completed

• Purchase of equipments -Completed

• Installation Qualification -Completed

• Operation Qualification -Completed

• Validation -Completed

• DCG(I) Inspection -Completed

• Trial Batches -Planned from May 2016

• Consistency Batches -Planned from Oct 2016

6. Release of Funds to M/s HLL:

The status of Funds approved under the project and released to M/s HLL as on date are as under;

Total Funds approved as per SFC Rs. 64.72 Crore

Funds released till March 2015 Rs. 57.78 Crore

Balancefunds to released Rs. 6.94 Cro

BRIEF ON CENTRAL RESEARCH INSTITUTE KASAULI

1. Introduction:

1.1. Origin & Concept:

Central Research Institute was established on 3rd May, 1905 as Pasteur Institute for North India. It is a subordinate office of Directorate general of Health Services, under the Ministry of Health & F.W. of India. Since its inception the institute has developed into a premier institute in research and production of a number immunobiologicals.

1.2. Estate & Physical Infrastructure:

Land Area: Estate of CRI Kasauli consists of 67 Acres of land in four pieces situated within a radius of 1.5. Kms. The reference areas are: (i) Manufacturing wing, (ii) R&D wing, (iii) Drum-bar Estate and (iv) Belvedere Estate. CRI Kasauli has residential accommodation that houses about350 employees. The institute has a huge complex which divided in seven sub-sections i.e. Establishment, Academic, Auxiliary Facilities, Production Division, Quality Control Division, Animal House and Research & Surveillance Division.

1.3. Mandate

Central Research Institute is engaged in

Large scale production of Bacterial and Viral Vaccines & Sera.
Research and Development in the field of immunology and vaccinology.
Teaching and training.
Quality Control of vaccine and sera

2. Staff Strength:

Total sanctioned staff strength -725
Staff in-position -460
Vacant positions -183
Lapsed posts -82

3.Budget Performance:

Budget performance (2015-16):

BE allocated is Rs. 5400.00 lakh
RE propose (2015-16) is Rs. 5376.13 Lakh
FE (2015-16) is Rs. 4220.27 Lakh
Budget utilization as on 31.3.2016 is Rs. 3890.83 lakh
BE(2016-17) Proposed is Rs. 7102.81 lakh

4.Technical Performance (2015-16):

Production and supplies of vaccine

Manufacturing in existing facilities has been started
Production in respect of DPT and TT is 41.16 lakh (16.14%) and 69.33% respectively.
Supply against demand in respect of DPT and TT is 69.33% and 33.66% respectively.

Details of Batches started, quantity manufactured, and demand received and quantity released is given in table 3.

Table No. 3

Production, demand and supply of the vaccine and anti-sera:

(Quantity in lakh of doses)

S. No	Vaccines & antisera	Installed Capacity	Production	% Produced	Demand	Supplies	% Supplied
1	DPT	255	41.16	16.14%	75.00	52.00	69.33%
2	DT	200	0
3	TT	300	35.19	11.735	101.71	34.71	33.66
4.1	YFV (CRIK)	0.35		0.00
4.2	YFV (IMPORT)		0.93		0.52	0.41	78.73%
5	ARS	2.5	0.22	8.96%	0.53	0.18	34.66
6	ASVS	3.00	0.015	5.06%	0.069	0.014	20.59%
7	DATS	0.80	0.051	6.4%	0.081	0.042	51.92%
8	NHS	0.004	0	0.00	0.0025	0.0001	4.44%
9	DR	2.75	0.14	5.06%	0.27	0.12	45.07%

Qty. in lakh of vials

5 . Surveillance activities

Samples received for;

Salmonella & E.coli -NIL
Rabies Research -NIL
Influenza Surveillance -105
Polio surveillance -4094

6. Research & Development

Number of projects in the beginning -Nil
Number new projects started -05
Number of projects Completed -Nil
Number of projects continuing at end -05

7. Medical care facilities provided;

OPD care -7194
Indoor Admissions -123
Lab Investigations -6366
Physiotherapy -617
Referral -37
YF Vaccination -2222
Medical Check up -282
Dog-bite cases -1034
ECG -319
Nebulization -231
Others -5209

1. Animal House

Equines -68
Sheep -14
Guiea Pigs -580
Mice -5250

2. Academic Activities

PG Courses -11
Project Work -03
Practical Training -34

Last Updated On 19/09/2017

DIRECTORATE GENERAL OF HEALTH SERVICES

Divisions

Public Health

INSTITUTE OF SEROLOGY KOLKATA